Prediction of the mechanism of ibrexafungerp as a UBE2M inhibitor can inhibit the neddylation pathway which can reduce tumor-promoting factors and increase levels of tumor suppressors thereby improving the occurrence of tumors and prognosis (Zheng et al., 2021). The gene discussed is UBE2M; the disease is neoplasm.